BLA - US Biologics license application

CTA - Global clinical trial application

CTR - EU clinical trial application

IND - US investigational new drug

MAA - EU Marketing authorisation

NDA - US 505(b)(1) and 505(b)(2) approval pathways

Biologics

Combination drug/device

New pharmaceuticals

Orphan

Autoimmune

Cardiovascular

Endocrine

Hepatology

Infectious disease

Neurology

Oncology

Ophthalmology

Rare disease

Respiratory

Treatment/pain

Asia Pacific

Canada

Europe

Latin America

United States

Briefing documents

Expanded access

Expedited programs

Initial INDs and maintenance

Marketing application support

Orphan designation

Pediatric programs

Regulatory reviews for documents

Application transfers

Due diligence

Gap analysis

Mentoring and training

Regulatory Intelligence